Product Type: | Suspension |
Brand Name: | Arlak Biotech |
Packaging Type | Bottle |
Packaging: | 30 ml |
Composition / Material Type: | Cefixime for oral Suspension IP |
Usages: | oral use |
FYCEF DRY SYRUP
COMPOSITION: -CEFIXIME 50 MG
Packing: - 30ML
M.R.P: - 65
Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.
PHARMACODYNAMICS: - Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.
Absorption : - About 40%-50% absorbed orally whether administered with or without food, however, time to maximal absorption is increased approximately 0.8 hours when administered with food.
Protein binding: - 65% (concentration independent)
Metabolism: - Hepatic. Approximately 50% of the absorbed dose is excreted unchanged in the urine in 24 hours.
Half-life: - 3-4 hours (may range up to 9 hours). In severe renal impairment (5 to 20 mL/min creatinine clearance), the half-life increased to an average of 11.5 hours.
INDICATION: - For use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:
(1) uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis,
(2) otitis media caused by Haemophilus influenzae (beta-lactamase positive and negative strains), Moraxella catarrhalis (most of which are beta-lactamase positive), and S. pyogenes,
(3) pharyngitis and tonsillitis caused by S. pyogenes,
(4) acute bronchitis and acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae (beta-lactamase positive and negative strains), and (5) uncomplicated gonorrhea (cervical/urethral) caused by Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains).